Phase 2
N=74
Intensive Glycemic Control for Congestive Heart Failure Exacerbation
Congestive Heart Failure · Diabetes Mellitus
Bottom Line
View on ClinicalTrials.gov: NCT00812253 ↗Enrolled (actual)
74
Serious AEs
0.0%
Results posted
Aug 2014
Primary outcome: Primary: Hospital Length of Stay — 7; 8 days
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 2
- Interventions
- Intravenous insulin (Drug); Subcutaneous insulin (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Kathleen Dungan
- Primary completion
- Sep 2013
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Hospital Length of Stay |
7; 8 | — |
| SECONDARY Hospital Readmission |
7; 15; 19; 24 | — |
| SECONDARY Heart Rate Variability |
5.1; 20.7 | — |
| SECONDARY Change in Quality of Life |
-22.4; -22.6 | — |
| SECONDARY Brain Natriuretic Peptide (BNP) |
794; 356 | — |
| SECONDARY Cardiac Output |
10.3; 8.6 | — |
Summary
Patients with heart failure often have high blood sugar (glucose).
Eligibility Criteria
Inclusion Criteria
- Age 18 and above
- Admitted (less than 48 hours) to the OSU Ross Heart Hospital with worsening heart failure
- Hyperglycemia or diabetes. Hyperglycemia is defined as blood glucose greater than 150 mg/dL on at least 2 occasions separated by at least 4 hours apart, insulin use, or HbA1c >6.5%.
Exclusion Criteria
- Type 1 diabetes
- Receiving comfort care measures only
- Hospital stay expected to be less than 2 days
- Pregnancy
- Prisoners
- Participation in the study on prior hospitalizations
- Acute myocardial infarction within 3 months
- End stage renal or liver disease
Data sourced from ClinicalTrials.gov (NCT00812253). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.